With an ideal proximity to the relevant markets and access to excellent research facilities and talented professionals, Singapore offers the best conditions to conquer the booming Asian markets. "We see the strong support of the Singaporean Economic Development Board (EDB) as proof of the attractiveness of our business and future model," states Prof. Dr. Claassen, the founder, Chairman of the Supervisory Board and main shareholder of the company, gratefully.

With its revolutionary implants Syntellix is now active in 30 countries and five out of six continents. The most recent approvals and market entries were succeeded in Australia, New Zealand and Saudi Arabia. Another 30 countries are currently in progress. In at least 17 of these countries the completion of the approval process and market entry is planned for 2017.

The new cortical bone screw will be launched as the third MAGNEZIX^® product line at the end of March. At least two new product lines are supposed to follow each year.

Download the international press release (EN)